Antibody molecules to C5aR1 and uses thereof
Antibody molecules that specifically bind to C5aR1 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as ANCA-vasculitis.
1. An antibody molecule capable of binding to complement component 5a receptor 1 (C5aR1), comprising a VH and a VL,
wherein the VH comprises:
i. an HCDR1 comprising an amino acid sequence of SEQ ID NO: 612;
ii. an HCDR2 comprising an amino acid sequence of SEQ ID NO: 732; and
iii. an HCDR3 comprising an amino acid sequence of SEQ ID NO: 852; and
wherein the VL comprises:
i. an LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acid residues from SEQ ID NO: 672,
ii. an LCDR2 comprising an amino acid sequence of SEQ ID NO: 792, and
iii. an LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acid residues from SEQ ID NO: 912.
2. A pharmaceutical composition comprising the antibody molecule of claim 1 , further comprising a pharmaceutically acceptable carrier or excipient.
3. A combination comprising the antibody molecule of claim 1 , and a second therapeutic agent.
4. The antibody molecule of claim 1 , comprising a VH and a VL,
wherein the VH comprises:
i. an HCDR1 comprising an amino acid sequence of SEQ ID NO: 612;
ii. an HCDR2 comprising an amino acid sequence of SEQ ID NO: 732; and
iii. an HCDR3 comprising an amino acid sequence of SEQ ID NO: 852; and
wherein the VL comprises:
iv. an LCDR1 comprising an amino acid sequence of SEQ ID NO: 672,
v. an LCDR2 comprising an amino acid sequence of SEQ ID NO: 792, and
vi. an LCDR3 comprising an amino acid sequence of SEQ ID NO: 912.